|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EIF1AX |
Gene summary for EIF1AX |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EIF1AX | Gene ID | 1964 |
| Gene name | eukaryotic translation initiation factor 1A X-linked | |
| Gene Alias | EIF1A | |
| Cytomap | Xp22.12 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | P47813 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1964 | EIF1AX | EEC-subject5 | Human | Endometrium | EEC | 2.34e-11 | -2.69e-01 | -0.249 |
| 1964 | EIF1AX | GSM5276934 | Human | Endometrium | EEC | 4.32e-20 | 1.42e-01 | -0.0913 |
| 1964 | EIF1AX | GSM5276937 | Human | Endometrium | EEC | 4.42e-12 | 3.05e-01 | -0.0897 |
| 1964 | EIF1AX | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.71e-34 | -1.98e-01 | -0.1869 |
| 1964 | EIF1AX | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 6.45e-39 | -2.11e-01 | -0.1875 |
| 1964 | EIF1AX | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.79e-41 | -2.29e-01 | -0.1883 |
| 1964 | EIF1AX | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.34e-40 | -2.32e-01 | -0.1934 |
| 1964 | EIF1AX | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 8.50e-59 | -3.12e-01 | -0.1917 |
| 1964 | EIF1AX | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 6.35e-58 | -3.36e-01 | -0.1916 |
| 1964 | EIF1AX | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 8.92e-11 | -1.87e-01 | -0.1269 |
| 1964 | EIF1AX | LZE2T | Human | Esophagus | ESCC | 7.90e-03 | 2.87e-01 | 0.082 |
| 1964 | EIF1AX | LZE4T | Human | Esophagus | ESCC | 1.92e-17 | 9.68e-01 | 0.0811 |
| 1964 | EIF1AX | LZE7T | Human | Esophagus | ESCC | 4.30e-11 | 1.31e+00 | 0.0667 |
| 1964 | EIF1AX | LZE8T | Human | Esophagus | ESCC | 5.52e-14 | 9.77e-01 | 0.067 |
| 1964 | EIF1AX | LZE22D1 | Human | Esophagus | HGIN | 6.97e-07 | -1.54e-01 | 0.0595 |
| 1964 | EIF1AX | LZE24T | Human | Esophagus | ESCC | 4.91e-05 | 4.21e-01 | 0.0596 |
| 1964 | EIF1AX | LZE6T | Human | Esophagus | ESCC | 1.19e-12 | 1.68e+00 | 0.0845 |
| 1964 | EIF1AX | P2T-E | Human | Esophagus | ESCC | 5.85e-52 | 1.17e+00 | 0.1177 |
| 1964 | EIF1AX | P4T-E | Human | Esophagus | ESCC | 1.01e-54 | 2.01e+00 | 0.1323 |
| 1964 | EIF1AX | P5T-E | Human | Esophagus | ESCC | 1.31e-57 | 1.49e+00 | 0.1327 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00064138 | Breast | Precancer | translational initiation | 30/1080 | 118/18723 | 3.23e-12 | 5.58e-10 | 30 |
| GO:000641313 | Breast | IDC | translational initiation | 31/1434 | 118/18723 | 7.29e-10 | 7.52e-08 | 31 |
| GO:000641323 | Breast | DCIS | translational initiation | 30/1390 | 118/18723 | 1.53e-09 | 1.43e-07 | 30 |
| GO:0006413 | Colorectum | AD | translational initiation | 45/3918 | 118/18723 | 1.35e-05 | 2.92e-04 | 45 |
| GO:00064131 | Colorectum | SER | translational initiation | 36/2897 | 118/18723 | 2.84e-05 | 7.63e-04 | 36 |
| GO:00064132 | Colorectum | MSS | translational initiation | 43/3467 | 118/18723 | 3.19e-06 | 9.38e-05 | 43 |
| GO:00064133 | Colorectum | MSI-H | translational initiation | 37/1319 | 118/18723 | 3.18e-15 | 8.83e-13 | 37 |
| GO:00064134 | Colorectum | FAP | translational initiation | 34/2622 | 118/18723 | 2.13e-05 | 5.12e-04 | 34 |
| GO:000641310 | Endometrium | AEH | translational initiation | 42/2100 | 118/18723 | 2.68e-12 | 4.67e-10 | 42 |
| GO:000641315 | Endometrium | EEC | translational initiation | 42/2168 | 118/18723 | 7.65e-12 | 1.24e-09 | 42 |
| GO:000641320 | Esophagus | HGIN | translational initiation | 55/2587 | 118/18723 | 7.33e-18 | 2.31e-15 | 55 |
| GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
| GO:000641312 | Liver | Cirrhotic | translational initiation | 76/4634 | 118/18723 | 8.36e-20 | 2.18e-17 | 76 |
| GO:000641322 | Liver | HCC | translational initiation | 94/7958 | 118/18723 | 1.39e-16 | 1.24e-14 | 94 |
| GO:000641332 | Liver | Cyst | translational initiation | 14/496 | 118/18723 | 2.93e-06 | 2.51e-04 | 14 |
| GO:000641318 | Oral cavity | OSCC | translational initiation | 96/7305 | 118/18723 | 4.02e-21 | 7.06e-19 | 96 |
| GO:000641319 | Oral cavity | LP | translational initiation | 75/4623 | 118/18723 | 3.96e-19 | 7.52e-17 | 75 |
| GO:000641333 | Oral cavity | NEOLP | translational initiation | 39/2005 | 118/18723 | 5.20e-11 | 6.30e-09 | 39 |
| GO:000641316 | Prostate | BPH | translational initiation | 59/3107 | 118/18723 | 4.78e-17 | 1.14e-14 | 59 |
| GO:000641317 | Prostate | Tumor | translational initiation | 66/3246 | 118/18723 | 2.57e-21 | 2.66e-18 | 66 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EIF1AX | SNV | Missense_Mutation | c.25N>C | p.Gly9Arg | p.G9R | P47813 | protein_coding | tolerated(0.09) | probably_damaging(0.991) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| EIF1AX | SNV | Missense_Mutation | c.295G>A | p.Glu99Lys | p.E99K | P47813 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
| EIF1AX | SNV | Missense_Mutation | c.23N>A | p.Gly8Glu | p.G8E | P47813 | protein_coding | tolerated(0.06) | probably_damaging(0.986) | TCGA-JW-A5VI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | topotecan | PD | |
| EIF1AX | SNV | Missense_Mutation | novel | c.9N>C | p.Lys3Asn | p.K3N | P47813 | protein_coding | deleterious(0) | benign(0.378) | TCGA-MY-A913-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EIF1AX | SNV | Missense_Mutation | c.210G>T | p.Trp70Cys | p.W70C | P47813 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G4-6298-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | irinotecan | PD | |
| EIF1AX | SNV | Missense_Mutation | c.210G>T | p.Trp70Cys | p.W70C | P47813 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| EIF1AX | SNV | Missense_Mutation | novel | c.37N>T | p.Arg13Cys | p.R13C | P47813 | protein_coding | deleterious(0.04) | probably_damaging(0.911) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| EIF1AX | SNV | Missense_Mutation | c.221N>T | p.Ser74Leu | p.S74L | P47813 | protein_coding | deleterious(0) | possibly_damaging(0.62) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| EIF1AX | SNV | Missense_Mutation | c.209N>C | p.Trp70Ser | p.W70S | P47813 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A06J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD | |
| EIF1AX | SNV | Missense_Mutation | c.38N>A | p.Arg13His | p.R13H | P47813 | protein_coding | tolerated(0.08) | possibly_damaging(0.693) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |